Zafgen Inc (NASDAQ:ZFGN) Stake Lessened by Algert Global LLC

Algert Global LLC lowered its holdings in Zafgen Inc (NASDAQ:ZFGN) by 27.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 19,070 shares of the biopharmaceutical company’s stock after selling 7,040 shares during the period. Algert Global LLC owned approximately 0.07% of Zafgen worth $195,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Zafgen in the 2nd quarter worth approximately $110,000. Barclays PLC lifted its holdings in shares of Zafgen by 139,086.7% in the 1st quarter. Barclays PLC now owns 20,878 shares of the biopharmaceutical company’s stock worth $155,000 after acquiring an additional 20,863 shares during the last quarter. A.R.T. Advisors LLC lifted its holdings in shares of Zafgen by 62.9% in the 1st quarter. A.R.T. Advisors LLC now owns 23,053 shares of the biopharmaceutical company’s stock worth $171,000 after acquiring an additional 8,904 shares during the last quarter. Element Capital Management LLC bought a new stake in shares of Zafgen in the 1st quarter worth approximately $174,000. Finally, Tibra Equities Europe Ltd bought a new stake in Zafgen during the 1st quarter valued at $377,000. 70.67% of the stock is currently owned by institutional investors.

In related news, insider Thomas E. Hughes sold 32,000 shares of the stock in a transaction dated Thursday, June 28th. The shares were sold at an average price of $10.00, for a total transaction of $320,000.00. Following the sale, the insider now directly owns 125,247 shares of the company’s stock, valued at approximately $1,252,470. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 23.70% of the stock is owned by corporate insiders.

ZFGN has been the subject of a number of recent analyst reports. Zacks Investment Research lowered shares of Zafgen from a “hold” rating to a “sell” rating in a report on Thursday, June 21st. ValuEngine upgraded shares of Zafgen from a “hold” rating to a “buy” rating in a report on Tuesday, June 26th. BidaskClub upgraded shares of Zafgen from a “hold” rating to a “buy” rating in a report on Tuesday, July 3rd. Cowen restated a “hold” rating on shares of Zafgen in a report on Monday, June 25th. Finally, Wedbush initiated coverage on shares of Zafgen in a report on Thursday, August 2nd. They issued an “outperform” rating and a $14.00 price objective for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $15.25.

Shares of NASDAQ:ZFGN traded up $0.12 during midday trading on Friday, reaching $9.52. The company’s stock had a trading volume of 126,000 shares, compared to its average volume of 271,741. The company has a market capitalization of $344.13 million, a PE ratio of -5.03 and a beta of -0.56. The company has a debt-to-equity ratio of 0.36, a current ratio of 8.42 and a quick ratio of 8.42. Zafgen Inc has a 12-month low of $3.24 and a 12-month high of $11.36.

Zafgen (NASDAQ:ZFGN) last released its earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.59) by $0.02. equities analysts anticipate that Zafgen Inc will post -2.05 EPS for the current fiscal year.

Zafgen Company Profile

Zafgen, Inc, a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders.

See Also: Growth Stocks, What They Are, What They Are Not

Institutional Ownership by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply